Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
115.77B
Market cap115.77B
Price-Earnings ratio
15.83
Price-Earnings ratio15.83
Dividend yield
4.43%
Dividend yield4.43%
Average volume
12.06M
Average volume12.06M
High today
$57.05
High today$57.05
Low today
$56.10
Low today$56.10
Open price
$56.69
Open price$56.69
Volume
4.64M
Volume4.64M
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $56.68, giving the company a market capitalization of 115.77B. It carries a P/E multiple of 15.83 and pays a dividend yield of 4.4%.

During the trading session on 2026-05-14, Bristol-Myers Squibb(BMY) shares reached a daily high of $57.05 and a low of $56.10. At a current price of $56.68, the stock is +1.0% higher than the low and still -0.6% under the high.

Trading activity shows a volume of 4.64M, compared to an average daily volume of 12.06M.

The stock's 52-week range extends from a low of $42.52 to a high of $62.89.

The stock's 52-week range extends from a low of $42.52 to a high of $62.89.

BMY News

Simply Wall St 14m
Bristol Myers Squibb Hengrui Deal Expands Pipeline And Valuation Upside Potential

Bristol Myers Squibb (NYSE:BMY) announced a global collaboration and licensing deal with Hengrui Pharma valued at up to $15.2 billion. The agreement covers joi...

Bristol Myers Squibb Hengrui Deal Expands Pipeline And Valuation Upside Potential
TipRanks 3h
Bristol-Myers Squibb Advances Navlimetostat With Key Phase 1 Tablet Study

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...

TipRanks 3h
Bristol-Myers Squibb Completes Key Afimetoran–Famotidine Interaction Study: What Investors Should Know

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...

Analyst ratings

58%

of 31 ratings
Buy
38.7%
Hold
58.1%
Sell
3.2%

More BMY News

Simply Wall St 2d
Bristol Myers Squibb Valuation Check After Recent Share Weakness And Mixed 2024 Earnings

Advertisement Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) has drawn fresh attention after recent trading left the stock d...

Bristol Myers Squibb Valuation Check After Recent Share Weakness And Mixed 2024 Earnings
Benzinga 2d
Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma

Bristol-Myers Squibb Co. (NYSE:BMY) on Tuesday announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology,...

Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma
The Wall Street Journal 3d
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up

Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals. Dado Ruvic / Reuters U.S. phar...

Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up
TipRanks 3d
Hengrui Pharma seals global collaboration and licensing deal with Bristol-Myers Squibb

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Seeking Alpha 3d
Bristol-Myers Squibb shares fell for seventh consecutive session

Bristol-Myers Squibb (BMY) shares fell for seven straight sessions, as the stock was down 0.9% at $55.64 on Monday. The New Jersey-based pharma giant fell 3.5%...

Bristol-Myers Squibb shares fell for seventh consecutive session
Simply Wall St 5d
EU Sotyktu Approval Tests Bristol-Myers Squibb’s Immunology And Earnings Story

European Commission approves Sotyktu (deucravacitinib) for adults with active psoriatic arthritis. First TYK2 inhibitor cleared for this indication in the Euro...

EU Sotyktu Approval Tests Bristol-Myers Squibb’s Immunology And Earnings Story
TipRanks 6d
Bristol-Myers Squibb Shareholders Approve Board and Compensation

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.